Zimmer Biomet delivered a strong Q2 2026, beating expectations and raising full-year guidance for both revenue and EPS. The company's growth was driven by momentum in hips, technology, and the SET portfolio, with the Paragon 28 acquisition performing above expectations. Reported Q2 revenue of $2.177B, up 4.8% reported and 4% organic constant currency, beating expectations.
Buzzberg readRaised full-year revenue and EPS guidanceZimmer Biomet delivered a strong Q2 2026, beating expectations and raising full-year guidance for both revenue and EPS. The company's growth was driven by momentum in hips, technology, and the SET portfolio, with the Paragon 28 acquisition performing above expectations. Reported Q2 revenue of $2.177B, up 4.8% reported and 4% organic constant currency, beating expectations.Read full analysisCollapse analysis
Zimmer Biomet delivered a strong Q2 2026, beating expectations and raising full-year guidance for both revenue and EPS. The company's growth was driven by momentum in hips, technology, and the SET portfolio, with the Paragon 28 acquisition performing above expectations. Reported Q2 revenue of $2.177B, up 4.8% reported and 4% organic constant currency, beating expectations.
Raised FY2026 organic growth guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, up from prior guidance.
Hip growth of 5.1% (cc) was led by strong performance in the U.S. (5.9%), driven by new product 'Hip Triple Play' and the iodine-coated hip launch in Japan, which is seeing supply constraints due to high demand.
Technology & Data segment grew 21.5%, with U.S. technology sales up over 50%, driven by robotics and capital sales.
Revenue$2.177B
+4% QoQ
EPS$2.07
-1% QoQ
Gross margin70.81%
reported
Op margin14.98%
reported
What changed this quarter
01
Guidance
Raised full-year revenue and EPS guidance
Guidance · revenue to 2.75%
02
M&A Integration
Paragon 28 growing mid-teens with negligible turnover
Reported Q2 revenue of $2.177B, up 4.8% reported and 4% organic constant currency, beating expectations.
03
New Products
Iodine-coated hip launch in Japan exceeding expectations
Raised FY2026 organic growth guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, up from prior guidance.
04
Commercial Strategy
U.S. sales force transition progressing faster than expected
Hip growth of 5.1% (cc) was led by strong performance in the U.S. (5.9%), driven by new product 'Hip Triple Play' and the iodine-coated hip launch in Japan, which is seeing supply constraints due to high demand.
AI, capex & demand read
AI
Platform & monetization
Management highlighted AI as a strategic priority, implementing AI initiatives to drive operational efficiency and margin improvement, and investing in AI applications through the Mobility Revolution Fund. They also mentioned OrthoGrid, an AI-based navigation solution for hip procedures, which had its strongest quarter to date.
Demand
Bookings & conversion
Management noted a healthy orthopedic procedural market and robust capital equipment pipeline, with record capital sales driven by robotics. They raised full-year revenue guidance, citing continued new product momentum and healthy underlying markets, while acknowledging some market noise with ACA exposure low single-digit. They expect growth to accelerate in the second half.
Tone · Upbeat
Management expressed strong confidence in execution, highlighted multiple product successes, raised guidance, and repeatedly emphasized momentum and excitement about future prospects.
Bottlenecks
Manufacturing capacityemerging
Iodine-coated hip platform supply struggling to keep pace with demand in Japan.
Supply constraints could limit near-term revenue growth and market share gains from this high-value product.
The launch of the iodine-coated hip platform in Japan is exceeding expectations, with demand so high that ZBH is struggling to supply at the necessary pace. This is a first-to-world technology, and ZBH is actively pursuing pathways to bring it to the US and other markets.
“Iodine. It's one of the most transformational products that this company has launched... the launch has gone much better than expected. Candidly, I mean, we're struggling to supply at the pace that we need to supply.”
ZBH is seeing deceleration in the reconstructive market due to payer mix shifts. Though ZBH's overall exposure to ACA exchanges and Medicaid is low single-digits, the aggregate impact of these coverage losses could create a headwind for procedure volumes.
“We keep monitoring this. I'll tell you, for us, the exposure to ACA and exchanges is low single digit. ... exposure to ACAs. We track all kinds of data...”
Management expects the second half of 2026 to show stronger growth compared to Q2, driven by easing supply constraints in Sports Medicine and continued acceleration in SET segments beyond Trauma and Restorative Therapies.
“So a combination of commercial execution, innovation, and the fact that the growth is not as acute as it may look at face value, give us confidence on delivering on the second half of 2026.”
RaisedGuidance · revenue to 2.75% · was IN LINE last Q
Forward guidance
Metric
Period
Range
Midpoint
Status
EPS
FY2026
$8.47–$8.59
$8.53
RAISED
Op margin
FY2026
50%
50%
MAINTAINED
Revenue
FY2026
2.25%–3.25%above vs consensus
2.75%
RAISED
Revenue
FY2026
3.9%–4.9%
4.4%
RAISED
Revenue
FY2026 Q3
50%
50%
GUIDED
UnitsSHARES_OUTSTANDING
FY2026
$193
$193
RAISED
Company read-throughs
PRGN
Private company
Investees
The acquired Paragon 28 is performing well, growing mid-teens, and is now the model for future acquisitions, indicating strong integration and synergies.
“Paragon 28 is growing mid-teens with commercial integration largely completed and negligible turnover among key team members. Paragon 28 now represents the template for future acquisitions.”
ZBH is seeing deceleration in the reconstructive market due to payer mix shifts. Though ZBH's overall exposure to ACA exchanges and Medicaid is low single-digits, the aggregate impact of these coverage losses could create a headwind for procedure volumes.